{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+and+Predominant+Negative+Symptoms", "query": { "condition": "Schizophrenia and Predominant Negative Symptoms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T09:03:34.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00922272", "title": "Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia and Predominant Negative Symptoms" ], "interventions": [ { "name": "SPD489 (lisdexamfetamine dimesylate)", "type": "DRUG" }, { "name": "Placebo matching SPD489 (lisdexamfetamine dimesylate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 92, "start_date": "2009-09-14", "completion_date": "2011-01-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00922272" }, { "nct_id": "NCT01760889", "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 low dose range (40mg, 80mg, and 100mg)", "type": "DRUG" }, { "name": "SPD489 high dose range (120mg, 140mg and 160mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2013-02-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 4, "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more", "locations": [ { "city": "Miami Springs", "state": "Florida" }, { "city": "O'Fallon", "state": "Missouri" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760889" }, { "nct_id": "NCT01738698", "title": "Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 40mg", "type": "DRUG" }, { "name": "SPD489 100mg", "type": "DRUG" }, { "name": "SPD489 160mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2012-11-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 1, "location_summary": "Irving, Texas", "locations": [ { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01738698" }, { "nct_id": "NCT01192906", "title": "A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "bitopertin [RO4917838]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 624, "start_date": "2010-12", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 21, "location_summary": "Carson, California • Oceanside, California • San Diego, California + 17 more", "locations": [ { "city": "Carson", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192906" }, { "nct_id": "NCT01760993", "title": "Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2013-02-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760993" }, { "nct_id": "NCT01192880", "title": "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Bitopertin", "type": "DRUG" }, { "name": "Antipsychotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 625, "start_date": "2010-11", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 27, "location_summary": "Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192880" }, { "nct_id": "NCT01192867", "title": "A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO4917838", "type": "DRUG" }, { "name": "Antipshychotics (Standard of Care)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 629, "start_date": "2010-12-11", "completion_date": "2014-05-26", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-07-24T09:03:34.118Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192867" } ] }